Home / Health / Appendix Cancer: Chemo Often Unnecessary, Study Finds
Appendix Cancer: Chemo Often Unnecessary, Study Finds
14 Sep
Summary
- Many rare appendix cancer patients may not need post-surgery chemotherapy.
- Chemotherapy did not prevent recurrence or improve survival in most cases.
- Gene mutations, not chemo, appear linked to cancer recurrence risk.
Many individuals diagnosed with rare appendix cancers may be able to forgo post-surgical chemotherapy, according to recent findings published on September 9 in JAMA Surgery. The research analyzed 202 patients who underwent surgery for stage 1 to 3 appendiceal cancer between 2000 and 2024.
Outcomes revealed that chemotherapy following surgery was not associated with a lower risk of cancer recurrence or improved patient survival. This challenges the conventional approach of treating appendix cancers similarly to colon cancers, which typically includes chemotherapy.
Instead, the study highlights that specific gene mutations within tumors appear to play a significant role in the likelihood of cancer recurrence. Researchers from MD Anderson Cancer Center suggest that a personalized approach, considering tumor histology and molecular features, is crucial for identifying patients who truly require closer monitoring.
The findings underscore the distinct biology of appendiceal cancers. The authors recommend genetic testing to determine which patients can safely skip chemotherapy, noting that further research is needed due to the study being conducted at a single institution.
